Showing 2831-2840 of 4166 results for "".
- Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilitieshttps://modernod.com/news/frontera-therapeutics-completes-160-million-series-b-financing-to-fund-clinical-development-and-manufacturing-capabilities/2480975/Frontera Therapeutics announced successful completion of a $160 million Series B funding round. In addition, Frontera announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate a first-in-human clinical trial of FT
- Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trialhttps://modernod.com/news/aldeyra-therapeutics-achieves-primary-endpoints-in-dry-eye-disease-chamber-crossover-clinical-trial/2480957/Aldeyra Therapeutics announced the achievement of the primary endpoints in a sequence-randomized, double-masked, vehicle-controlled crossover clinical trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. Reproxalap was st
- Phase 3 Clinical Study IND Accepted in China for Alimera’s Fluocinolone Acetonide Intravitreal Implanthttps://modernod.com/news/phase-3-clinical-study-ind-accepted-in-china-for-alimeras-fluocinolone-acetonide-intravitreal-implant/2480901/Alimera Sciences announced that its partner, Ocumension Therapeutics, received approval from the National Medical Products Administration for its IND application to begin the phase 3 clinical study for fluocinolone acetonide intravitreal implant in support of a filing for marketing approval
- Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at ARVOhttps://modernod.com/news/kala-pharmaceuticals-to-present-clinical-data-for-kpi-012-its-mesenchymal-stem-cell-secretome-product-for-the-treatment-of-pced-at-arvo/2480824/Kala Pharmaceuticals reported clinical data from a phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of severe ocular diseases driven by impaired healing. As previously disclosed, treatment with KPI-012 was well tolerated and resulted in significant improvements
- Visus Therapeutics Announces Appointment of Julia Williams as Vice President of Clinical and Medical Affairs and Expansion of Irvine Co-Headquartershttps://modernod.com/news/visus-therapeutics-announces-appointment-of-julia-williams-as-vice-president-of-clinical-and-medical-affairs-and-expansion-of-irvine-co-headquarters/2480703/Visus Therapeutics announced the appointment of eye care industry veteran Julia Williams as vice president of clinical and medical affairs. The company also announced the expansion of its Irvine co-headquarters in the University of California-Irvine Research Park, including the establishment
- Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink Therapyhttps://modernod.com/news/glaukos-announces-commencement-of-phase-2-corneal-health-clinical-program-for-third-generation-ilink-therapy/2480696/Glaukos announced that it has commenced a phase 2 clinical program for its third-generation iLink therapy designed to treat keratoconus. Glaukos’ iLink pharmaceutical platform consists of novel single-use drug formulations that are bio-activa
- Iveric Bio Announces Foveal Anatomy Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura in Patients with GAhttps://modernod.com/news/iveric-bio-announces-foveal-anatomy-post-hoc-analysis-from-gather1-clinical-trial-of-zimura-in-patients-with-ga/2480635/Iveric bio announced a post-hoc analysis which evaluated various geographic atrophy (GA) growth parameters to explore the rate of disease progression within various regions in the fovea in a subset of patients from the GATHER1 Zimura (avacincaptad pegol) phase 3 clinical trial for the treatm
- Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trials for Presbyopia and Dry Eye Diseasehttps://modernod.com/news/glaukos-announces-first-patient-enrolled-in-phase-2-clinical-trial-for-presbyopia/2480564/Glaukos announced that it has enrolled the first patient into a phase 2 clinical trial of GLK-302 for the treatment of presbyopia and GLK-301 for the treatment of signs and symptoms of dry eye disease (DED). GLK-302 is the second investigational drug candidate utilizing Glaukos&rsq
- Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucomahttps://modernod.com/news/ivantis-announces-first-patient-enrolled-in-pivotal-clinical-trial-evaluating-the-hydrus-microstent-in-standalone-migs-for-mild-to-moderate-glaucoma/2480515/Ivantis announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery. Up to 80% of glaucoma patients have mild to moderate disease severity, and a sta
- Eyenuk Announces Publication of Strong EyeArt Pivotal Clinical Trial Results in JAMA Network Openhttps://modernod.com/news/eyenuk-announces-publication-of-strong-eyeart-pivotal-clinical-trial-results-in-jama-network-open/2480451/Eyenuk announced that strong results from the EyeArt prospective, multicenter pivotal clinical trial were published as an original investigation in JAMA Network Open, a peer-reviewed medical journal published by the American Medical Association. The artic